| 1990 |
Kamada founded in Israel to develop and produce life-saving injectable pharmaceuticals |
| |
 |
| |
| 1991 |
First product - Albumin |
| |
|
| |
| 1998 |
10 products marketed in 15 countries |
| |
|
| |
| 2000 |
New business strategy implemented:
 |
Focus on specialty products |
|
Strategic partnerships and cooperation |
|
Targeting and penetration to US and EU markets |
|
Increasing investments in R&D |
|
| |
|
| |
| 2003 |
Completion of intravenous AAT Phase I clinical trials |
| |
|
| |
| 2004 |
Orphan Drug Designation for aerosolized AAT in the US and EU |
| |
|
| |
| 2005 |
|
Kamada becomes Israel’s first public biopharmaceutical company |
|
Alpha-1 patients are treated with Kamada's intravenous AAT product |
|
| |
|
| |
| 2006 |
|
FDA approval for intravenous AAT Phase III clinical plans |
|
Strategic agreement with PARI (German-based world leader for inhalation solutions) to develop an aerosolized AAT product |
|
EMEA approval for aerosolized AAT Phase I clinical trials |
|
Annual sales reach $13M |
|
New research laboratories in Weizmann Science Park |
|
| |
|
| |
| 2007 |
|
Intravenous AAT Phase III clinical trials start in the US |
|
Aerosolized AAT Phase I clinical trials show positive results |
|
EMEA approval for aerosolized AAT Phase II-III clinical plans for the treatment of Alpha-1 Antitrypsin |
|
Aerosolized AAT Phase II clinical trials for CF begin in Israel following the EMEA's approval |
|
FDA approval for KamRAB anti-rabies immune drug Phase II-III clinical plans |
|
Strategic collaboration agreements |
|
Plant upgrade to comply with FDA and EMEA requirements |
|
| |
|
| |
| 2008 |
| |
|
Kamada Signs a $20M Financing Agreement with Hercules Technology Growth Capital |
|
|
| |
|
Kamada Announces Successful Completion of Phase I Studies with Aerosolized AAT for the Treatment of Lung Diseases |
|
| |
|
Kamada to Start Phase II Clinical Studies with its Aerosolized AAT for the Treatment of Bronchiectasis |
|
| |
|
Kamada and PARI Expand Collaboration: The new agreements include a long term supply agreement as well as the exclusive license to use PARIs eFlow electronic drug nebulizer with additional indications for Kamada's AAT drug |
|
| |
|
Kamada Signs a $ 4 Million Private Equity Investment Agreement with Shavit Capital Fund |
|
| |
|
Company successfuly met primary endpoint in Phase III clinical trials in the US with its flagship product - Intravenous AAT (Alpha-1 Antitrypsin) |
|
| |
Kamada Announces Successful Interim Results of Phase II Deposition Study with
Aerosolized AAT |
| |
Kamada Prepares for Phases II-III in Europe with its Aerosolized AAT/ Announces successful Completion of Quality Audit |
| |
Phase II with AAT to treat CF has been completed |
